Overview

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Status:
Not yet recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

This is an open label, non-randomized, 2-stage phase II, single arm study to determine the efficacy of NY-ESO-1 peptide vaccine as a priming mechanism to prevent anti-PD1 resistance in patients with platinum-refractory stage III/IV ovarian cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Georgetown University

Collaborator:

United States Department of Defense

Treatments:

Nivolumab